Earnings Call Summary | BioCardia(BCDA.US) Q1 2024 Earnings Conference
Earnings Call Summary | BioCardia(BCDA.US) Q1 2024 Earnings Conference
The following is a summary of the BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript:
以下是BioCardia, Inc.（BCDA）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
BioCardia reported $55,000 revenue for Q1 2024, similar to Q1 2023's revenue.
The company reduced expenses significantly by 35% compared to the previous quarter, thanks to decreased research and development costs and selling, general and administrative expenses.
BioCardia managed to lower the net loss for Q1 2024 down to $2.3 million, a notable decrease from Q1 2023's net loss of $3.5 million.
BioCardia公佈的2024年第一季度收入爲55,000美元，與2023年第一季度的收入相似。
與上一季度相比，該公司的支出大幅減少了35％，這要歸因於研發成本以及銷售、一般和管理費用降低。
BioCardia設法將2024年第一季度的淨虧損降至230萬美元，較2023年第一季度的350萬美元淨虧損顯著下降。
Business Progress:
業務進展：
BioCardia has completed the enrollment for the CardiAMP Heart Failure trial and anticipates presenting final results for scientific and regulatory submission in Q4 2024.
The company initiated the CardiAMP Heart Failure II trial approved by the FDA and continued progress in other trials for ischemic heart conditions.
BioCardia has established new delivery partnerships with StemCardia and CellProthera, as part of their continuous growth and development strategy.
BioCardia已經完成了Cardiamp心力衰竭試驗的註冊，預計將在2024年第四季度公佈最終結果以提交科學和監管部門。
該公司啓動了美國食品藥品管理局批准的Cardiamp心力衰竭II試驗，其他缺血性心臟病試驗繼續取得進展。
作爲持續增長和發展戰略的一部分，BioCardia已與Stemcardia和CellProthera建立了新的交付合作夥伴關係。
More details: BioCardia IR
更多詳情： BioCardia IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。